Salvage Leksell Stereotactic Radiosurgery for Malignant Gliomas.

Salvage Leksell Stereotactic Radiosurgery for Malignant Gliomas. Prog Neurol Surg. 2019 May 16;34:191-199 Authors: Niranjan A, Kano H, Monaco Iii EA, Lunsford LD Abstract The outcome of patients with malignant gliomas has not substantially improved, even with advances in imaging, neurosurgery, molecular subtyping, and radiation, and newer oncologic options. Maximal safe resection when feasible remains the initial treatment of choice for most malignant gliomas. These tumors often recur and require additional therapy to control the tumor growth. Leksell stereotactic radiosurgery (SRS) is offered as salvage therapy in patients with recurrent or residual malignant gliomas. SRS is well tolerated and is associated with a relatively low risk of adverse radiation effects in malignant glial tumor patients who otherwise have relatively few options. SRS allows the surgeon more flexibility in terms of surgical options and may enhance quality of life for patients postoperatively. Although randomized controlled studies are lacking in the use of salvage SRS after the failure of initial standard of care management, preliminary data suggest that radiosurgery improves tumor control and overall survival for patients with recurrent malignant gliomas. PMID: 31096255 [PubMed - as supplied by publisher]
Source: Progress in Neurological Surgery - Category: Neurosurgery Tags: Prog Neurol Surg Source Type: research